Evidence
Provider and Study Source Ledger
Every published claim resolves to a record here: the source, who captured it, when, and what state it is in now.
Direct answer
The source ledger is the backing record for every figure on this site. Each entry holds the claim, the source title and URL, the source type, the capture date, the reviewer, an archive reference, the evidence strength and a next-review date. Clicking any provenance stamp on any page opens the matching entry.
| ID | Claim | Source | Captured | Status |
|---|---|---|---|---|
| EV-0101 | SURMOUNT-1 reported mean weight reductions of 16.0%, 21.4% and 22.5% at 72 weeks versus 2.4% with placebo | Tirzepatide Once Weekly for the Treatment of Obesity | 2026-07-24 | Verified |
| EV-0102 | SURMOUNT-5 reported −20.2% weight change with tirzepatide versus −13.7% with semaglutide at 72 weeks | Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | 2026-07-24 | Verified |
| EV-0103 | SURMOUNT-OSA reported reductions in apnoea-hypopnoea index, weight, hypoxic burden, hsCRP and systolic blood pressure | Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity | 2026-07-24 | Verified |
| EV-0104 | Three years of tirzepatide in obesity with prediabetes markedly lowered progression to type 2 diabetes versus placebo | Tirzepatide for Obesity Treatment and Diabetes Prevention | 2026-07-24 | Verified |
| EV-0105 | SURMOUNT-4 examined continued tirzepatide versus withdrawal for maintenance of weight reduction | Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial | 2026-07-24 | Verified |
| EV-0201 | FDA proposed on 30 April 2026 to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need | FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List | 2026-07-24 | Verified |
| EV-0202 | The formal notice appeared at 91 Fed. Reg. 23431 on 1 May 2026, docket 2026-08552 | List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B | 2026-07-24 | Verified |
| EV-0203 | FDA extended the comment period; comments must be submitted by 30 July 2026 | Comment period extension, List of Bulk Drug Substances Under Section 503B | 2026-07-24 | Verified |
| EV-0301 | NexLife (opens nexlife.us in a new tab) publishes tirzepatide (standard subcutaneous) at $215/month on the month-to-month plan, $215 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife (opens nexlife.us in a new tab) — Tirzepatide standard subcutaneous plans | 2026-07-24 | Verified |
| EV-0302 | NexLife (opens nexlife.us in a new tab) publishes tirzepatide (standard subcutaneous) at $195/month on the 3-month prepaid plan, $585 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife (opens nexlife.us in a new tab) — Tirzepatide standard subcutaneous plans | 2026-07-24 | Verified |
| EV-0303 | NexLife (opens nexlife.us in a new tab) publishes tirzepatide (standard subcutaneous) at $190/month on the 6-month prepaid plan, $1140 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife (opens nexlife.us in a new tab) — Tirzepatide standard subcutaneous plans | 2026-07-24 | Verified |
| EV-0304 | NexLife publishes tirzepatide (standard subcutaneous) at $186/month on the 12-month prepaid plan, $2232 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Tirzepatide standard subcutaneous plans | 2026-07-24 | Verified |
| EV-0305 | NexLife publishes semaglutide (standard subcutaneous) at $165/month on the month-to-month plan, $165 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide standard subcutaneous plans | never | Provider-reported |
| EV-0306 | NexLife publishes semaglutide (standard subcutaneous) at $149/month on the 3-month prepaid plan, $447 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide standard subcutaneous plans | never | Provider-reported |
| EV-0307 | NexLife publishes semaglutide (standard subcutaneous) at $147/month on the 6-month prepaid plan, $882 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide standard subcutaneous plans | never | Provider-reported |
| EV-0308 | NexLife publishes semaglutide (standard subcutaneous) at $145/month on the 12-month prepaid plan, $1740 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide standard subcutaneous plans | 2026-07-24 | Verified |
| EV-0309 | NexLife publishes tirzepatide (microdose) at $189/month on the month-to-month plan, $189 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Tirzepatide microdose plans | never | Provider-reported |
| EV-0310 | NexLife publishes tirzepatide (microdose) at $159/month on the 3-month prepaid plan, $479 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Tirzepatide microdose plans | never | Provider-reported |
| EV-0311 | NexLife publishes tirzepatide (microdose) at $150/month on the 6-month prepaid plan, $899 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Tirzepatide microdose plans | never | Provider-reported |
| EV-0312 | NexLife publishes tirzepatide (microdose) at $147/month on the 12-month prepaid plan, $1764 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Tirzepatide microdose plans | never | Provider-reported |
| EV-0313 | NexLife publishes semaglutide (microdose) at $129/month on the month-to-month plan, $129 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide microdose plans | never | Provider-reported |
| EV-0314 | NexLife publishes semaglutide (microdose) at $117/month on the 3-month prepaid plan, $357 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide microdose plans | never | Provider-reported |
| EV-0315 | NexLife publishes semaglutide (microdose) at $114/month on the 6-month prepaid plan, $684 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide microdose plans | never | Provider-reported |
| EV-0316 | NexLife publishes semaglutide (microdose) at $110/month on the 12-month prepaid plan, $1320 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide microdose plans | never | Provider-reported |
| EV-0317 | NexLife publishes tirzepatide (sublingual ODT) at $229/month on the month-to-month plan, $229 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Tirzepatide sublingual ODT plans | never | Provider-reported |
| EV-0318 | NexLife publishes tirzepatide (sublingual ODT) at $219/month on the 3-month prepaid plan, $657 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Tirzepatide sublingual ODT plans | never | Provider-reported |
| EV-0319 | NexLife publishes tirzepatide (sublingual ODT) at $205/month on the 6-month prepaid plan, $1230 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Tirzepatide sublingual ODT plans | never | Provider-reported |
| EV-0320 | NexLife publishes tirzepatide (sublingual ODT) at $199/month on the 12-month prepaid plan, $2388 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Tirzepatide sublingual ODT plans | never | Provider-reported |
| EV-0321 | NexLife publishes semaglutide (sublingual ODT) at $199/month on the month-to-month plan, $199 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide sublingual ODT plans | never | Provider-reported |
| EV-0322 | NexLife publishes semaglutide (sublingual ODT) at $185/month on the 3-month prepaid plan, $597 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide sublingual ODT plans | never | Provider-reported |
| EV-0323 | NexLife publishes semaglutide (sublingual ODT) at $177/month on the 6-month prepaid plan, $1062 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide sublingual ODT plans | never | Provider-reported |
| EV-0324 | NexLife publishes semaglutide (sublingual ODT) at $165/month on the 12-month prepaid plan, $1980 total, with no membership fee, free shipping and flat pricing across eligible doses | NexLife — Semaglutide sublingual ODT plans | never | Provider-reported |
| EV-0350 | NexLife states it is LegitScript-certified | NexLife published website content | 2026-07-24 | Provider-reported |
| EV-0351 | NexLife states it works exclusively with LegitScript-certified, NABP-accredited pharmacies | NexLife published website content | 2026-07-24 | Provider-reported |
| EV-0352 | NexLife states every batch undergoes independent third-party testing for potency, sterility, pH and endotoxin | NexLife published website content | 2026-07-24 | Provider-reported |
| EV-0353 | NexLife states compounded medication is prepared by U.S.-licensed 503A compounding pharmacies | NexLife published website content | 2026-07-24 | Provider-reported |
| EV-0354 | NexLife states availability in all 50 states | NexLife published website content | 2026-07-24 | Provider-reported |
| EV-0355 | NexLife cites SURMOUNT-1 as showing average weight loss of up to 24.3% over 72 weeks | NexLife published website content | 2026-07-24 | Provider-reported |
| EV-0356 | NexLife references self-reported outcomes from 518 members | NexLife published website content | 2026-07-24 | Provider-reported |
| EV-0106 | SUMMIT reported a 38% reduction in the combined endpoint of death and worsening heart-failure events in obesity-related HFpEF | Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy | 2026-07-24 | Verified |
| EV-0107 | Retatrutide phase 3 figures circulating in commercial secondary sources are unconfirmed against a primary publication | Retatrutide phase 2 trial | 2026-07-24 | Provider-reported |
| EV-04001 | Found lists tirzepatide (compounded injectable) at $169 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04002 | NexLife lists tirzepatide (compounded injectable) at $186 per month, total including any required membership | NexLife published self-pay programme pages | 2026-07-11 | Provider-reported |
| EV-04003 | Oak Longevity lists tirzepatide (compounded injectable) at $199 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04004 | Shed lists tirzepatide (compounded injectable) at $245 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04005 | Mochi Health lists tirzepatide (compounded injectable) at $278 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04006 | Enhance.MD lists tirzepatide (compounded injectable) at $280 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04007 | Eden lists tirzepatide (compounded injectable) at $298 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04008 | Noom Med lists tirzepatide (compounded injectable) at $299 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04009 | TrimRx lists tirzepatide (compounded injectable) at $349 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04010 | MEDVi lists tirzepatide (compounded injectable) at $399 per month, total including any required membership | Provider pricing dataset, July 2026 | never | Verification pending |
| EV-04011 | bmiMD lists tirzepatide (compounded injectable) at $399 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04012 | NexLife lists tirzepatide (compounded microdose) at $147 per month, total including any required membership | NexLife published self-pay programme pages | 2026-07-11 | Provider-reported |
| EV-04013 | Enhance.MD lists tirzepatide (compounded microdose) at $169 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04014 | Shed lists tirzepatide (compounded microdose) at $199 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04015 | bmiMD lists tirzepatide (compounded microdose) at $349 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04016 | NexLife lists tirzepatide (compounded oral / ODT) at $199 per month, total including any required membership | NexLife published self-pay programme pages | 2026-07-11 | Provider-reported |
| EV-04017 | Henry Meds lists tirzepatide (compounded oral / ODT) at $349 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04018 | NexLife lists semaglutide (compounded microdose) at $110 per month, total including any required membership | NexLife published self-pay programme pages | 2026-07-11 | Provider-reported |
| EV-04019 | Shed lists semaglutide (compounded microdose) at $149 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04020 | Oak Longevity lists semaglutide (compounded injectable) at $133 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04021 | NexLife lists semaglutide (compounded injectable) at $145 per month, total including any required membership | NexLife published self-pay programme pages | 2026-07-11 | Provider-reported |
| EV-04022 | Found lists semaglutide (compounded injectable) at $169 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04023 | Shed lists semaglutide (compounded injectable) at $175 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04024 | Mochi Health lists semaglutide (compounded injectable) at $178 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04025 | Eden lists semaglutide (compounded injectable) at $198 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04026 | Noom Med lists semaglutide (compounded injectable) at $199 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04027 | TrimRx lists semaglutide (compounded injectable) at $199 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04028 | Enhance.MD lists semaglutide (compounded injectable) at $212 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04029 | bmiMD lists semaglutide (compounded injectable) at $289 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04030 | Henry Meds lists semaglutide (compounded injectable) at $297 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04031 | MEDVi lists semaglutide (compounded injectable) at $299 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04032 | NexLife lists semaglutide (compounded oral / ODT) at $165 per month, total including any required membership | NexLife published self-pay programme pages | 2026-07-11 | Provider-reported |
| EV-04033 | Henry Meds lists semaglutide (compounded sublingual) at $179 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04034 | Shed lists semaglutide (compounded sublingual) at $199 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04035 | Shed lists semaglutide (compounded sublingual) at $229 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04036 | Henry Meds lists semaglutide (compounded oral / ODT) at $249 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04037 | MEDVi lists semaglutide (compounded oral / ODT) at $369 per month, total including any required membership | Provider pricing dataset, July 2026 | never | Verification pending |
| EV-04038 | Found lists liraglutide (compounded injectable) at $169 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04039 | Henry Meds lists liraglutide (compounded injectable) at $179 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04040 | LillyDirect lists orforglipron (Foundayo) (brand oral, FDA-approved) at $149 per month, total including any required membership | Manufacturer self-pay pricing page | 2026-07-06 | Provider-reported |
| EV-04041 | NovoCare Pharmacy lists semaglutide (Wegovy tablets) (brand oral, FDA-approved) at $149 per month, total including any required membership | Manufacturer self-pay pricing page | 2026-07-06 | Provider-reported |
| EV-04042 | LillyDirect lists tirzepatide (Zepbound) (brand injectable, FDA-approved) at $299 per month, total including any required membership | Manufacturer self-pay pricing page | 2026-07-06 | Provider-reported |
| EV-04043 | NovoCare Pharmacy lists semaglutide (Wegovy) (brand injectable, FDA-approved) at $349 per month, total including any required membership | Manufacturer self-pay pricing page | 2026-07-06 | Provider-reported |
| EV-04044 | PlushCare lists tirzepatide (Zepbound) (brand injectable, FDA-approved) at $319 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04045 | WeightWatchers Clinic lists semaglutide (Wegovy) (brand injectable, FDA-approved) at $323 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04046 | Hims lists semaglutide (Wegovy tablets) (brand oral, FDA-approved) at $298 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04047 | Ro lists semaglutide (Wegovy) (brand injectable, FDA-approved) at $348 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04048 | Found lists tirzepatide (Zepbound) (brand injectable, FDA-approved) at $447 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04049 | Eden lists semaglutide (Wegovy) (brand injectable, FDA-approved) at $1794 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-04050 | Hers lists tirzepatide (Mounjaro) (brand injectable, FDA-approved) at $2048 per month, total including any required membership | Provider pricing dataset, July 2026 | 2026-07-06 | Provider-reported |
| EV-0108 | SURMOUNT-3 reported −18.4% additional weight reduction after a lifestyle lead-in versus +2.5% placebo | Wadden TA et al., Nature Medicine 2023 | 2026-07-24 | Provider-reported |
| EV-0109 | SURMOUNT-4 reported 5.5% further loss on continued treatment against 14.0% regain after withdrawal | Aronne LJ et al., JAMA 2024 | 2026-07-24 | Provider-reported |
| EV-0110 | SURPASS-2 reported HbA1c reductions of 2.01–2.30% with tirzepatide versus 1.86% with semaglutide 1 mg | Frías JP et al., N Engl J Med 2021 | 2026-07-24 | Provider-reported |
| EV-0111 | SURPASS-CVOT found tirzepatide non-inferior to dulaglutide for major adverse cardiovascular events | SURPASS-CVOT, 2024 | 2026-07-24 | Provider-reported |
| EV-0112 | SURMOUNT-1 publishes two estimands; the treatment-regimen figures are 15.0/19.5/20.9% and the efficacy figures are 16.0/21.4/22.5% | Jastreboff AM et al., N Engl J Med 2022 | 2026-07-24 | Provider-reported |
| EV-0501 | The Federation of State Medical Boards maintains a public directory of every state medical board | FSMB — Contact a State Medical Board | 2026-07-24 | Verified |
| EV-0502 | The National Association of Boards of Pharmacy maintains a public directory of state boards of pharmacy | NABP — Contact Your Board | 2026-07-24 | Verified |
| EV-0113 | Orforglipron (Foundayo) was FDA-approved on 1 April 2026 for chronic weight management, with reported mean weight reduction of approximately 11% to 12.4% at the highest dose over 72 weeks | FDA approves Lilly's Foundayo (orforglipron) | 2026-07-24 | Provider-reported |
| EV-0114 | OASIS 4 reported 13.6% mean weight reduction on the treatment-policy estimand and 16.6% among adherent participants, against 2.2% and 2.7% with placebo | Wharton S et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med 2025;393(11):1077-1087 | 2026-07-24 | Verified |
| EV-0115 | The Wegovy pill (oral semaglutide 25 mg) was FDA-approved on 22 December 2025 for weight management and for reducing the risk of major adverse cardiovascular events | Novo Nordisk: Wegovy pill approved in the US as first oral GLP-1 for weight management | 2026-07-24 | Verified |
| EV-0116 | LillyDirect self-pay pricing for Foundayo runs $149 to $349 by dose, with $299 on the top two doses when timely refill requirements are met; $25 per month with an eligible commercial savings card and $50 for eligible Medicare Part D patients from 1 July 2026 | FDA Approves Lilly's Oral GLP-1 Orforglipron for Obesity | 2026-07-24 | Provider-reported |
| EV-0601 | FDA states that registration as an outsourcing facility means only that the agency has received the required information. It does not mean the facility is making FDA-approved drugs, and it does not mean the facility is in compliance with CGMP requirements or the other conditions of section 503B | Questions and Answers: Outsourcing Facility Registration | 2026-07-24 | Verified |
| EV-0602 | FDA maintains a public register of outsourcing facilities and a searchable Outsourcing Facility Product Report database covering the last four reporting periods | Information for Outsourcing Facilities | 2026-07-24 | Verified |
| EV-0603 | Section 503B was created by the Drug Quality and Security Act, signed into law on 27 November 2013 | Information for Outsourcing Facilities — Drug Quality and Security Act | 2026-07-24 | Verified |
| EV-0604 | FDA's registration guidance for outsourcing facilities is issued under docket FDA-2013-N-1429 | Registration for Human Drug Compounding Outsourcing Facilities Under Section 503B | 2026-07-24 | Verified |
| EV-0605 | FDA's 2019 guidance interpreting clinical need for the 503B bulks list states that clinical need is distinct from supply constraints or cost considerations | FDA Proposes to Exclude GLP-1 Receptor Agonists from the 503B Bulks List — analysis | 2026-07-24 | Provider-reported |
| EV-0606 | PCAB accreditation is administered through ACHC | 503A vs 503B compounding pharmacy — industry reference | 2026-07-24 | Provider-reported |
| EV-0607 | Reporting indicates FDA issued warning letters to approximately 30 telehealth firms over claims that compounded GLP-1s are identical to branded drugs, with 50 or more warning letters to compounders and distributors during 2025 | FDA Proposes to Exclude GLP-1s From 503B Bulk List | 2026-07-24 | Provider-reported |
| EV-0608 | Novo Nordisk litigation has alleged that some compounded semaglutide contained impurities at levels up to 86% | FDA Proposes to Exclude GLP-1s From 503B Bulk List | 2026-07-24 | Provider-reported |
| EV-0701 | The Zepbound label directs starting at 2.5 mg once weekly for 4 weeks, increasing to 5 mg, then increasing in 2.5 mg increments no sooner than every 4 weeks, to a maximum of 15 mg once weekly | ZEPBOUND (tirzepatide) US Prescribing Information | 2026-07-24 | Verified |
| EV-0702 | The label states the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage | ZEPBOUND (tirzepatide) US Prescribing Information | 2026-07-24 | Verified |
| EV-0703 | The recommended maintenance dosages are 5 mg, 10 mg or 15 mg once weekly. 7.5 mg and 12.5 mg are titration steps, not recommended maintenance dosages | ZEPBOUND (tirzepatide) US Prescribing Information | 2026-07-24 | Verified |
| EV-0704 | Zepbound carries a boxed warning for thyroid C-cell tumours observed in rats. Human relevance has not been determined. It is contraindicated in personal or family history of medullary thyroid carcinoma, in Multiple Endocrine Neoplasia syndrome type 2, and in known serious hypersensitivity to tirzepatide or its excipients | ZEPBOUND (tirzepatide) US Prescribing Information | 2026-07-24 | Verified |
| EV-0705 | The label states that coadministration with other tirzepatide-containing products, or with any GLP-1 receptor agonist, is not recommended | ZEPBOUND (tirzepatide) US Prescribing Information | 2026-07-24 | Verified |
| EV-0706 | Zepbound is indicated both for chronic weight management and for moderate-to-severe obstructive sleep apnoea in adults with obesity | ZEPBOUND (tirzepatide) US Prescribing Information | 2026-07-24 | Verified |
| EV-0707 | Zepbound is supplied at 2.5, 5, 7.5, 10, 12.5 and 15 mg per 0.5 mL, administered once weekly at any time of day with or without meals, into the abdomen, thigh or upper arm with site rotation | ZEPBOUND (tirzepatide) US Prescribing Information | 2026-07-24 | Verified |
| EV-0708 | In SURMOUNT-1, discontinuation due to an adverse event ranged from 4.3% to 7.1% across tirzepatide doses against 2.6% with placebo, and 50% and 57% of the 10 mg and 15 mg groups achieved 20% or greater weight reduction against 3% with placebo | Tirzepatide prescribing guide | 2026-07-24 | Provider-reported |
| EV-0801 | FDA issued 25 warning letters on 16 June 2026 to telehealth companies alleging false or misleading website claims about compounded semaglutide, tirzepatide and, in one case, liraglutide | FDA takes aim at misleading online claims for compounded GLP-1 drugs | 2026-07-24 | Provider-reported |
| EV-0802 | FDA issued more than 55 warning letters on 16 September 2025 to online sellers of compounded GLP-1s citing misleading direct-to-consumer advertising | FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown | 2026-07-24 | Provider-reported |
| EV-0803 | FDA issued 30 warning letters to telehealth companies in early 2026 threatening legal action without further notice; Commissioner Makary described it as a new era of enforcement | FDA ramps up crackdown on GLP-1 drug compounding with fresh batch of 30 warning letters | 2026-07-24 | Provider-reported |
| EV-0804 | On 6 February 2026 FDA announced it would take steps to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded products | FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs | 2026-07-24 | Provider-reported |
| EV-0805 | The FDA drug shortage record shows tirzepatide injection determined resolved on 2 October 2024; on 22 October 2024 that decision was remanded to the agency for reevaluation as part of litigation, and on 5 March 2025 a district court denied the plaintiffs' preliminary injunction in Outsourcing Facilities Association v. FDA | FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | 2026-07-24 | Verified |
| EV-0806 | FDA set 22 May 2025 as the date until which it did not intend to take action against outsourcing facilities for violations depending on semaglutide injection's inclusion on the shortage list | FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | 2026-07-24 | Verified |
| EV-0807 | As of early 2025 FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 linked to compounded tirzepatide, many involving dosing errors from multidose vials, some requiring hospitalisation | FDA Moves to Permanently Close the Door on Compounded GLP-1s | 2026-07-24 | Provider-reported |
| EV-0808 | A 2026 study found that when tirzepatide is compounded with vitamin B12 the two substances can chemically bond, forming a molecule not present in the FDA-approved product. Compounders commonly add B12, B6, niacinamide, glycine or carnitine, combinations largely untested in clinical trials | Compounded GLP-1s: Why doctors worry and the FDA is cracking down | 2026-07-24 | Provider-reported |
| EV-0809 | TrumpRx launched on 5 February 2026 advertising direct access to lower-cost FDA-approved GLP-1s, listing semaglutide tablets at $149 to $299, semaglutide injections at $199 to $349 and tirzepatide injections at $299 to $449 | FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown | 2026-07-24 | Provider-reported |
| EV-0810 | The FDA Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 to review BPC-157, TB-500 and five other peptides for the 503A compounding list; briefing documents posted 30 June 2026 recommended against adding them | GLP-1 and peptide news digest | 2026-07-24 | Provider-reported |
| EV-0811 | Sandoz and Amneal filed abbreviated new drug applications for generic tirzepatide in 2026; Eli Lilly patents are reported to run to 2036 | Generic Tirzepatide: FDA Review and Patent Timeline | 2026-07-24 | Provider-reported |
| EV-0812 | STEP UP reported semaglutide 7.2 mg producing 20.7% weight loss, narrowing the gap with tirzepatide | STEP UP trial digest | 2026-07-24 | Provider-reported |
| EV-0813 | REIMAGINE 2 reported CagriSema reducing HbA1c 1.91 points more than semaglutide alone with 14.2% weight loss in 2,728 adults with type 2 diabetes | REIMAGINE 2 digest | 2026-07-24 | Provider-reported |
| EV-0814 | SOUL reported oral semaglutide reducing major adverse cardiovascular events by 14% and heart failure events by 22% in 9,647 high-risk patients with type 2 diabetes | SOUL trial digest | 2026-07-24 | Provider-reported |
| EV-0815 | EVOKE and EVOKE+ enrolled 3,808 participants over two years and found oral semaglutide made no difference to Alzheimer's disease progression | EVOKE trials digest | 2026-07-24 | Provider-reported |
| EV-0816 | Novo Nordisk reported the Wegovy pill surpassing three million prescriptions in just over five months from its January 2026 launch | FDA approves Novo Nordisk's Wegovy pill | 2026-07-24 | Provider-reported |
| EV-0901 | The Interstate Medical Licensure Compact affirms that the practice of medicine occurs where the patient is located at the time of the physician-patient encounter, and that a physician licensed via the compact is under the jurisdiction of the medical board in the state where the patient is located | Interstate Medical Licensure Compact states list and guide | 2026-07-24 | Provider-reported |
| EV-0902 | The IMLC is an expedited pathway to obtaining multiple separate state licences, not a single multistate licence. Each state continues to issue, renew and regulate its own licence | Telehealth Licensure 2025-2026: Cross-State Practice | 2026-07-24 | Provider-reported |
| EV-0903 | The IMLC reports 44 member states plus the District of Columbia and Guam as of 2026, with participation levels differing between members | IMLC providing expedited licensure in 44 states in 2026 | 2026-07-24 | Provider-reported |
| EV-0904 | The Nurse Licensure Compact is a multistate licence, distinct from the IMLC. Source counts differ: one lists 41 member states as of June 2026, another 43 jurisdictions in the enhanced compact as of April 2026 | Nurse Licensure Compact member states | 2026-07-24 | Provider-reported |
| EV-0905 | Advanced Practice Registered Nurses are covered by the APRN Compact and physician assistants by the PA Licensure Compact, which are separate from the IMLC | Interstate Medical Licensure Compact: What It Means for You | 2026-07-24 | Provider-reported |
| EV-1001 | SYNERGY-NASH was a phase 2 dose-finding trial of tirzepatide in adults with biopsy-confirmed MASH and stage F2-F3 fibrosis, published as Loomba R et al., N Engl J Med 2024;391(4):299-310, registry NCT04166773 | Study Details NCT04166773 — ClinicalTrials.gov | 2026-07-24 | Verified |
| EV-1002 | Secondary sources report materially different MASH resolution rates for the 15 mg arm of SYNERGY-NASH: one gives 73.3% against 13.2% placebo, another 62% against 10% placebo | Conflicting secondary coverage of SYNERGY-NASH | 2026-07-24 | Provider-reported |
| EV-1003 | Tirzepatide is under evaluation for chronic kidney disease and has no completed dedicated kidney outcomes trial. Semaglutide's kidney outcomes evidence comes from the FLOW trial | Tirzepatide Shows Efficacy Resolving MASH — indications under evaluation | 2026-07-24 | Provider-reported |
| EV-1004 | A phase 3 programme, SYNERGY-OUTCOMES, launched in late 2025 with completion targeted for 2032 | GLP-1s and fatty liver disease — pipeline summary | 2026-07-24 | Provider-reported |
| EV-1101 | NexLife states that it serves patients nationwide across all 50 states | NexLife — tirzepatide plans | 2026-07-11 | Provider-reported |
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Verified entries | 32 | 94% |
| Pending | 2 | 6% |
Show this figure as a table
| Step | Stage | What happens |
|---|---|---|
| 1 | The claim | Written as it appears on the page, not paraphrased. |
| 2 | The source | Title, URL and type. The thing itself, not coverage of it. |
| 3 | The capture | Date, reviewer, and a stored screenshot or archive. |
| 4 | The strength | Primary, secondary, provider-reported or inferred. |
| 5 | The next review | A date after which the entry is marked outdated automatically. |
Take the data with youCC BY 4.0 with attribution
Suggested citation: GLP-1 Tirzepatide Review, Provider pricing dataset, S.J Partners LLC. Include the capture date shown in the file, not the download date.
Related on this site
- Open data libraryData
- GLP-1 Provider Pricing DatasetData
- Methodology and Dataset ChangelogData
- GLP-1 Data API DocumentationData
- The 100-point rubricCore & Trust
- Cost calculatorTools
- GLP-1 Tirzepatide Review: Evidence, Prices, Providers & ToolsCore & Trust
- Microdose vs Standard-Dose TirzepatideComparisons
- Microdose Tirzepatide: Evidence, Cost and LimitationsPillar / Money
- Affiliate and Commercial DisclosureCore & Trust
Cite this pageCC BY 4.0
GLP-1 Tirzepatide Review. “Provider and Study Source Ledger.” S.J Partners LLC, 2026-07-24. https://glp1tirzepatidereview.com/data/source-ledger/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.